Basic Information
| LncRNA/CircRNA Name | NORAD |
| Synonyms | NA |
| Region | GRCh38_20:36045622-36050960 |
| Ensemble | ENSG00000260032 |
| Refseq | NR_027451 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | ovarian cancer |
| ICD-0-3 | C56.9 |
| Methods | qPCR, Western blot, Luciferase reporter assay |
| Sample | human ovarian epithelial cell line HOEpiC and five human ovarian cancer cell lines SKOV3, Caov3, A2780, HO-8910 and OVCAR3, ovarian tumour tissues, non-tumour tissues |
| Expression Pattern | up-regulated |
| Function Description | NORAD was upregulated in ovarian cancer tissues and cells. Silencing of NORAD lessened cell viability, migration and invasion, but induced apoptosis of SKOV3 cells, whereas overexpression of NORAD had opposite effects. Moreover, PG decreased the expression of NORAD. Overexpression of NORAD reversed the effects of PG treatment on the cell biological performances of SKOV3 cells, which were further reversed after overexpression of miR-608 simultaneously. Furthermore, STAT3 was tested as a target gene of miR-608, and the impact of NORAD in PG-treated SKOV3 cells were through the miR-608-mediated STAT3. |
| Pubmed ID | 31299866 |
| Year | 2019 |
| Title | Involvement of NORAD/miR-608/STAT3 axis in carcinostasis effects of physcion 8-O-?- glucopyranoside on ovarian cancer cells |
External Links
| Links for NORAD | GenBank HGNC NONCODE |
| Links for ovarian cancer | OMIM COSMIC |